Compare GSL & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GSL | ANAB |
|---|---|---|
| Founded | 2007 | 2005 |
| Country | Greece | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.4B |
| IPO Year | 2006 | 2017 |
| Metric | GSL | ANAB |
|---|---|---|
| Price | $36.23 | $47.57 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 12 |
| Target Price | $39.00 | ★ $60.18 |
| AVG Volume (30 Days) | 295.7K | ★ 482.0K |
| Earning Date | 03-04-2026 | 02-26-2026 |
| Dividend Yield | ★ 6.93% | N/A |
| EPS Growth | ★ 24.38 | N/A |
| EPS | ★ 11.14 | N/A |
| Revenue | ★ $747,044,000.00 | $169,467,000.00 |
| Revenue This Year | $7.45 | $135.51 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $3.24 | ★ N/A |
| Revenue Growth | 6.50 | ★ 196.42 |
| 52 Week Low | $17.73 | $12.21 |
| 52 Week High | $37.22 | $52.47 |
| Indicator | GSL | ANAB |
|---|---|---|
| Relative Strength Index (RSI) | 56.42 | 54.75 |
| Support Level | $34.74 | $44.25 |
| Resistance Level | $36.90 | $48.53 |
| Average True Range (ATR) | 0.85 | 2.96 |
| MACD | 0.00 | -0.20 |
| Stochastic Oscillator | 64.53 | 66.35 |
Global Ship Lease Inc operates in the container shipping industry. The company owns and charters out containerships under long-term, fixed-rate charters to container liner companies. The majority of the company's revenues are derived from charters to MAERSK. Its fleet consisted of more than 60 containerships.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).